New Reference: Zenocutuzumab for NRG1 Fusion-Positive Cancer
Study
Phase 2, open-label, multicenter clinical trial (eNRGy)
|
Advanced/metastatic solid tumors with NRG1 fusion
|
Zenocutuzumab 750 mg IV every 2 weeks
|
Efficacy
ORR: 30% (95% CI, 23–37)
|
CR: 1 pt
|
mDoR: 11.1 mos (95% CI, 7.4–12.9)
|
mPFS: 6.8 mos (95% CI, 5.5–9.1)
|
NSCLC ORR: 29% (95% CI, 20–39), mDoR: 12.7 mos (95% CI, 7.4–20.4)
|
Pancreatic cancer ORR: 42% (95% CI, 25–59), mDoR: 7.4 mos (95% CI, 4.0–11.2)
|
Safety
Grade ≥3 AEs: 14%
|
Most common grade ≥3 AEs: Anemia (5%), GGT increase (4%), pneumonia (3%)
|
Infusion-related reactions: 14% (all grade 1–2)
|
Treatment-related grade ≥3 AEs: 7% (most common: diarrhea, anemia—3% each)
|
Fatal AEs: 4% (none treatment-related)
|
Schram AM,Goto K,Kim DW Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Reviewed by Ulas D. Bayraktar, MD on Feb 7, 2025
